Stanford Discovers 'Natural Ozempic' BRP Molecule Through AI — Appetite Suppression Without Nausea or Muscle Loss

The AI-identified BRP molecule acts directly on the appetite control center in the brain, reducing meal consumption and body fat in animals while avoiding GLP-1 side effects like nausea, constipation, and muscle loss. Meanwhile, new research indicates approximately 10% of people carry genetic variants conferring 'GLP-1 resistance,' making them nonresponsive to Ozempic and Wegovy.